Treating Depression in the Medically Ill

Psychiatric Clinics of North America

Volumn 30, Issue 1, 2007, Pages 77-90

  Iosifescu, Dan V ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DEXAMETHASONE; INTERLEUKIN 2; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR;

ASTHMA; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CRITICAL ILLNESS; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERTENSION; MAJOR DEPRESSION; OUTCOMES RESEARCH; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; STROKE;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HEALTH STATUS; HUMANS;

EID: 33847715470     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2006.12.008     Document Type: Review

References (125)

1. Krishnan K.R., Delong M., Kraemer H., et al. Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry 52 6 (2002) 559-588
2. Gillespie L. The clinical differentiation of types of depression. Guys Hosp rep 79 (1929) 231-233
3. Lewis A. Melancholia: a clinical survey of depressive states. J Ment Sci 80 (1934) 277-378
4. Klerman G.L. Depression in the medically ill. Psychiatr Clin North Am 4 (1981) 301-317
5. Andreasen N.C., and Winokur G. Secondary depression: familial, clinical, and research perspectives. Am J Psychiatry 136 1 (1979) 62-66
6. Akiskal H.S., Rosenthal R.H., Rosenthal T.L., et al. Differentiation of primary affective illness from situational, symptomatic, and secondary depressions. Arch Gen Psychiatry 36 6 (1979) 635-643
7. Hirschfeld R.M., Klerman G.L., Andreasen N.C., et al. Situational major depressive disorder. Arch Gen Psychiatry 42 11 (1985) 1109-1114
8. Frasure-Smith N., Lesperance F., and Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 270 15 (1993) 1819-1825
9. Frasure-Smith N., Lesperance F., and Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 91 4 (1995) 999-1005
10. Bush D.E., Zigelstein R.C., Tayback M., et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 88 (2001) 337-341
11. Kauhanen M., Korpelainen J.T., Hiltunen P., et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 30 9 (1999) 1875-1880
12. Jorge R.E., Robinson R.G., Arndt S., et al. Mortality and post-stroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 160 10 (2003) 1823-1829
13. de Groot M., Anderson R., Freedland K.E., et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 63 4 (2001) 619-630
14. Spiegel D., and Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54 3 (2003) 269-282
15. Ganzini L., Smith D.M., Fenn D.S., et al. Depression and mortality in medically ill older adults. J Am Geriatr Soc 45 3 (1997) 307-312
16. Covinsky K.E., Kahana E., Chin M.H., et al. Depressive symptoms and 3-year mortality in older hospitalized medical patients. Ann Intern Med 130 7 (1999) 563-569
17. Rudisch B., and Nemeroff C.B. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 54 3 (2003) 227-240
18. Schleifer S.J., Macari-Hinson M.M., Coyle D.A., et al. The nature and course of depression following myocardial infarction. Arch Intern Med 149 8 (1989) 1785-1789
19. Ziegelstein R.C., Fauerbach J.A., Stevens S.S., et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 160 12 (2000) 1818-1823
20. Lesperance F., Frasure-Smith N., and Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 58 2 (1996) 99-110
21. Aben I., Verhey F., Strik J., et al. A comparative study into the one-year cumulative incidence of depression after stroke and myocardial infarction. J Neurol Neurosurg Psychiatry 74 5 (2003) 581-585
22. Carney R.M., Rich M.W., Tevelde A., et al. Major depressive disorder in coronary artery disease. Am J Cardiol 60 16 (1987) 1273-1275
23. Dew M.A., Roth L.H., Schulberg H.C., et al. Prevalence and predictors of depression and anxiety-related disorders during the year after heart transplantation. Gen Hosp Psychiatry 18 6 Suppl (1996) 48S-61S
24. Jiang W., Alexander J., Christopher E., et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 161 15 (2001) 1849-1856
25. Turvey C.L., Schultz K., Arndt S., et al. Prevalence and correlates of depressive symptoms in a community sample of people suffering from heart failure. J Am Geriatr Soc 50 12 (2002) 2003-2008
26. Mast B.T., MacNeill S.E., and Lichtenberg P.A. Post-stroke and clinically-defined vascular depression in geriatric rehabilitation patients. Am J Geriatr Psychiatry 12 1 (2004) 84-92
27. Rabkin J.G., Charles E., and Kass F. Hypertension and DSM-III depression in psychiatric outpatients. Am J Psychiatry 140 8 (1983) 1072-1074
28. Bosworth H.B., Bartash R.M., Olsen M.K., et al. The association of psychosocial factors and depression with hypertension among older adults. Int J Geriatr Psychiatry 18 12 (2003) 1142-1148
29. Hamalainen J., Kaprio J., Isometsa E., et al. Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. J Epidemiol Community Health 55 8 (2001) 573-576
30. Scarinci I.C., Thomas J., Brantley P.J., et al. Examination of the temporal relationship between smoking and major depressive disorder among low-income women in public primary care clinics. Am J Health Promot 16 6 (2002) 323-330
31. Wulsin L.R., and Singal B.M. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 65 2 (2003) 201-210
32. Lesperance F., Frasure-Smith N., Talajic M., et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 105 9 (2002) 1049-1053
33. Robinson R.G., Starr L.B., and Price T.R. A two-year longitudinal study of mood disorders following stroke. Prevalence and duration at six months follow-up. Br J Psychiatry 144 (1984) 256-262
34. Astrom M., Adolfsson R., and Asplund K. Major depression in stroke patients. A 3-year longitudinal study. Stroke 24 7 (1993) 976-982
35. Cassidy E., O'Connor R., and O'Keane V. Prevalence of post-stroke depression in an Irish sample and its relationship with disability and outcome following inpatient rehabilitation. Disabil Rehabil 26 2 (2004) 71-77
36. Robinson R.G. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 54 3 (2003) 376-387
37. House A., Knapp P., Bamford J., et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 32 3 (2001) 696-701
38. Brown L.C., Majumdar S.R., Newman S.C., et al. Type 2 diabetes does not increase risk of depression. CMAJ 175 1 (2006) 42-46
39. Sturm J.W., Donnan G.A., Dewey H.M., et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 35 10 (2004) 2340-2345
40. Jonas B.S., Franks P., and Ingram D.D. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Fam Med 6 (1997) 43-49
41. Davidson K., Jonas B.S., Dixon K.E., et al. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary artery risk development in young adults. Arch Intern Med 160 (2000) 1495-1500
42. Jess P., and Eldrup J. The personality patterns in patients with duodenal ulcer and ulcer-like dyspepsia and their relationship to the course of the diseases. Hvidovre Ulcer Project Group. J Intern Med 235 6 (1994) 589-594
43. Levenstein S., Kaplan G.A., and Smith M.W. Psychological predictors of peptic ulcer incidence in the Alameda County Study. J Clin Gastroenterol 24 3 (1997) 140-146
44. Gavard J.A., Lustman P.J., and Clouse R.E. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 16 8 (1993) 1167-1178
45. Anderson R.J., Freedland K.E., Clouse R.E., et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24 6 (2001) 1069-1078
46. Brown L.C., Majumdar S.R., Newman S.C., et al. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 28 5 (2005) 1063-1067
47. Katon W., von Korff M., Ciechanowski P., et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care 27 4 (2004) 914-920
48. McDaniel J.S., Musselman D.L., Porter M.R., et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 52 (1995) 89-99
49. Brown K.W., Levy A.R., Rosberger Z., et al. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med 65 4 (2003) 636-643
50. Penninx B.W., Guralnik J.M., Pahor M., et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90 24 (1998) 1888-1893
51. Koenig H.G., Meador K.G., Cohen H.J., et al. Depression in elderly hospitalized patients with medical illness. Arch Intern Med 148 9 (1988) 1929-1936
52. Koenig H.G., Meador K.G., Shelp F., et al. Major depressive disorder in hospitalized medically ill patients: an examination of young and elderly male veterans. J Am Geriatr Soc 39 9 (1991) 881-890
53. Wells K.B., Rogers W., Burnam A., et al. How the medical comorbidity of depressed patients differs across health care settings: results from the Medical Outcomes Study. Am J Psychiatry 148 12 (1991) 1688-1696
54. Patten S.B. Long-term medical conditions and major depression in the Canadian population. Can J Psychiatry 44 2 (1999) 151-157
55. Watkins L.L., Schneiderman N., Blumenthal J.A., et al. ENRICHD Investigators. Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction. Am Heart J 146 1 (2003) 48-54
56. Stein M.B., Cox B.J., Afifi T.O., et al. Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. Psychol Med 36 5 (2006) 587-596
57. Frasure-Smith N., Lesperance F., Prince R.H., et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet 350 9076 (1997) 473-479
58. Nelson J.C., Kennedy J.S., Pollock B.G., et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 156 7 (1999) 1024-1028
59. Strik J.J., Honig A., Lousberg R., et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 62 6 (2000) 783-789
60. Glassman A.H., O'Connor C.M., Califf R.M., et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288 6 (2002) 701-709
61. Berkman L.F., Blumenthal J., Burg M., et al. Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 89 23 (2003) 3106-3116
62. Taylor C.B., Youngblood M.E., Catellier D., et al. ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62 7 (2005) 792-798
63. Andersen G., Vestergaard K., and Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25 6 (1994) 1099-1104
64. Robinson R.G., Schultz S.K., Castillo C., et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 157 3 (2000) 351-359
65. Wiart L., Petit H., Joseph P.A., et al. Fluoxetine in early post-stroke depression: a double-blind placebo-controlled study. Stroke 31 8 (2000) 1829-1832
66. Fruehwald S., Gatterbauer E., Rehak P., et al. Early fluoxetine treatment of post-stroke depression-a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 250 3 (2003) 347-351
67. Choi-Kwon S., Han S.W., Kwon S.U., et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 37 1 (2006) 156-161
68. Narushima K., Kosier J.T., and Robinson R.G. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 190 5 (2002) 296-303
69. Almeida O.P., Waterreus A., and Hankey G.J. Preventing depression after stroke: results from a randomized placebo-controlled trial. J Clin Psychiatry 67 7 (2006) 1104-1109
70. Goodnick P.J. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 13 1 (2001) 31-41
71. Lustman P.J., Griffith L.S., Clouse R.E., et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 59 3 (1997) 241-250
72. Lustman P.J., Freedland K.E., Griffith L.S., et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23 5 (2000) 618-623
73. Lustman P.J., Griffith L.S., Freedland K.E., et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 129 8 (1998) 613-621
74. Katon W.J., Von Korff M., Lin E.H., et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 61 10 (2004) 1042-1049
75. Williams S., and Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 94 3 (2006) 372-390
76. van Heeringen K., and Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 169 4 (1996) 440-443
77. Razavi D., Allilaire J.F., Smith M., et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94 (1996) 205-210
78. Morrow G.R., Hickok J.T., Roscoe J.A., et al. Differential effects of paroxetine on fatigue and depression: a randomized double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Program. J Clin Oncol 21 (2003) 4635-4641
79. Roscoe J.A., Morrow G.R., Hickok J.T., et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89 (2005) 243-249
80. Holland J.C., Romano S.J., Heiligenstein J.H., et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 7 (1998) 291-300
81. Pezzella G., Moslinger-Gehmayr R., and Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70 (2001) 1-10
82. Ash G., Dickens C.M., Creed F.H., et al. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology (Oxford) 38 10 (1999) 959-967
83. Bird H., and Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study. J Rheumatol 27 12 (2000) 2791-2797
84. Parker J.C., Smarr K.L., Slaughter J.R., et al. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. Arthritis Rheum 49 6 (2003) 766-777
85. Popkin M.K., Callies A.L., and Mackenzie T.B. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 42 (1985) 1160-1163
86. Koenig H.G., Goli V., Shelp F., et al. Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial. J Gen Intern Med 4 6 (1989) 498-505
87. Keitner G.I., Ryan C.E., Miller I.W., et al. 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 148 3 (1991) 345-350
88. Small G.W., Birkett M., Meyers B.S., et al. Impact of physical illness on quality of life and antidepressant response in geriatric major depression: Fluoxetine Collaborative Study Group. J Am Geriatr Soc 44 (1996) 1220-1225
89. Evans M., Hammond M., Wilson K., et al. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry 12 8 (1997) 817-824
90. Evans M., Hammond M., Wilson K., et al. Treatment of depression in the elderly: effect of physical illness on response. Int J Geriatr Psychiatry 12 12 (1997) 1189-1194
91. Koike A.K., Unutzer J., and Wells K.B. Improving the care for depression in patients with comorbid medical illness. Am J Psychiatry 159 10 (2002) 1738-1745
92. Oslin D.W., Datto C.J., Kallan M.J., et al. Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc 50 5 (2002) 823-828
93. Papakostas G.I., Petersen T., Iosifescu D.V., et al. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res 118 2 (2003) 183-188
94. Iosifescu D.V., Nierenberg A.A., Alpert J.E., et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 160 12 (2003) 2122-2127
95. Perlis R.H., Iosifescu D.V., Alpert J.E., et al. Medical comorbidity does not moderate response to augmentation or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Psychosomatics 45 3 (2004) 224-229
96. Alexopoulos G.S., Meyers B.S., Robert Y.C., et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 57 3 (2000) 285-290
97. Iosifescu D.V., Nierenberg A.A., Alpert J.E., et al. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics 45 (2004) 419-425
98. Simon G.E., Von Korff M., and Lin E. Clinical and functional outcomes of depression treatment in patients with and without chronic medical illness. Psychol Med 35 2 (2005) 271-279
99. Bogner H.R., Cary M.S., Bruce M.L., et al. The role of medical comorbidity in outcome of major depression in primary care: the PROSPECT study. Am J Geriatr Psychiatry 13 10 (2005) 861-868
100. Harpole L.H., Williams Jr. J.W., Olsen M.K., et al. Improving depression outcomes in older adults with comorbid medical illness. Gen Hosp Psychiatry 27 1 (2005) 4-12
101. Ciechanowski P.S., Katon W.J., and Russo J.E. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 160 21 (2000) 3278-3285
102. DeVane C.L. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19 4 (1999) 443-466
103. Brown E.S., Varghese F.P., and McEwen B.S. Association of depression with medical illness: does cortisol play a role?. Biol Psychiatry 55 1 (2004) 1-9
104. Arana G.W., Baldessarini J.R., and Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatry 42 (1985) 1193-1204
105. Lenox R.H., Teyser J.M., Rothschild B., et al. Failure to normalize the dexamethasone suppression test: association with length of illness. Biol Psychiatry 20 (1985) 329-352
106. Targum S.D. Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse. Biol Psychiatry 19 3 (1984) 305-318
107. Young E.A., Lopez J.F., Murphy-Weinberg V., et al. Hormonal evidence for altered responsiveness to social stress in major depression. Neuropsychopharmacology 23 4 (2000) 411-418
108. McEwen B.S. Effects of adverse experiences for brain structure and function. Biol Psychiatry 48 8 (2000) 721-731
109. Sheline Y.I., Wang P.W., Gado M.H., et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 93 9 (1996) 3908-3913
110. Steffens D.C., Byrum C.E., McQuoid D.R., et al. Hippocampal volume in geriatric depression. Biol Psychiatry 48 (2000) 301-309
111. Krakoff L.R. Glucocorticoid excess syndromes causing hypertension. Cardiol Clin 6 4 (1988) 537-545
112. Lechin F., van der Dijs B., Rada I., et al. Plasma neurotransmitters and cortisol in duodenal ulcer patients. Role of stress. Dig Dis Sci 35 11 (1990) 1313-1319
113. Roy M.S., Roy A., and Brown S. Increased urinary-free cortisol outputs in diabetic patients. J Diabetes Complications 12 1 (1998) 24-27
114. Hricik D.E., Mayes J.T., and Schulak J.A. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 18 3 (1991) 353-358
115. Dunn A.J., Swiergiel A.H., and de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 29 4-5 (2005) 891-909
116. Gottsater A., Forsblad J., Matzsch T., et al. Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies. J Intern Med 251 1 (2002) 61-68
117. Stenvinkel P., Heimburger O., and Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39 2 (2002) 274-282
118. Cottone S., Mule G., Amato F., et al. Amplified biochemical activation of endothelial function in hypertension associated with moderate to severe renal failure. J Nephrol 15 6 (2002) 643-648
119. van der Meer I.M., de Maat M.P., Bots M.L., et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 22 5 (2002) 838-842
120. Reid P.T., and Sallenave J.M. Cytokines in the pathogenesis of chronic obstructive pulmonary disease. Curr Pharm Des 9 1 (2003) 25-38
121. Woodman R.J., Watts G.F., Puddey I.B., et al. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension. Atherosclerosis 163 1 (2002) 175-181
122. Yirmiya R., Pollak Y., Morag M., et al. Illness, cytokines, and depression. Ann N Y Acad Sci 917 (2000) 478-487
123. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. In: Dantzer R., Wollman E.E., and Yirmiya R. (Eds). Cytokines, stress and depression (1999), Kluwer Academic/Plenum Publishers, New York 75-81
124. Dantzer R., Wollman E., Vitkovic L., et al. Cytokines and depression: fortuitous or causative association. Mol Psychiatry 4 4 (1999) 328-332
125. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav Immun 15 1 (2001) 7-24